Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: What happened to the new generation anxiolytics? » 3 Beer Effect

Posted by Sparkboy on June 5, 2002, at 0:56:23

In reply to What happened to the new generation anxiolytics?, posted by 3 Beer Effect on June 4, 2002, at 0:03:03

> 2. New Serotonin 5HT-1A Agonists?
> Where are the new Serotonin 5HT1-A agonists that are supposed to replace the largely dissapointing med Buspar?- such as Gepirone ER, Tandospirone, Flesinoxan?
>
> (Found this written year 2000 (2 yrs ago)- "Gepirone ER, a chemical cousin of Buspar is continuing in clinical development in the United States & Tandospirone in Japan."
> "Ipsaspirone, Sunepitron, Transdermal Buspar & others have been dropped from clinical development, although there may be some continuting interest in Flesinoxan or others."
>

>I thought a whole bunch of new generation anxiolytics were in the pipeline/ going to be approved by the
> FDA?

Hello, 3 Beer. I started to say this question answers itself; look no further than the 3 letter government acronym. But that'd sound full of bitterness and misdirected hostility. Instead, I'll show you what Google spit out for me yesterday. Gepirone is especially promising for atypical depression, my own interest. I wonder if it's available in Europe.

Take it easy.
--John

PS: gepirone has been bouncing around in research since ~1985. You'd think if it were dangerous, they'd know that by now.


Thursday April 11, 9:33 am Eastern Time

Press Release

SOURCE: Akzo Nobel

Organon to consult with FDA on Ariza -gepirone ER-

ARNHEM/OSS, The Netherlands--(BUSINESS WIRE)--April 11, 2002--Akzo Nobel (NASDAQ:AKZOY - news), the multinational healthcare, coatings and chemicals company, today announced Akzo Nobel's business unit Organon has received a letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for marketing authorization of gepirone ER tablets (also known as Ariza).

The letter mentions issues that will have to be addressed before the product can be approved. Organon has already contacted the FDA about providing additional information or clarification as necessary.

Organon has confidence in the NDA it submitted in May 2001, and trusts in its ability to satisfactorily address the issues presented in the letter. However, approval of the product is dependent upon the outcome of consultation with the FDA. It is not possible to provide more information with regard to marketing authorization until after receipt of further response from the FDA. It is expected, however, that contrary to previous announcements the product will not be introduced in 2002.

Ariza is a new drug for the treatment of patients with major depressive disorders.


Share
Tweet  

Thread

 

Post a new follow-up

Your message only Include above post


Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:Sparkboy thread:108599
URL: http://www.dr-bob.org/babble/20020602/msgs/108723.html